

## Appendix 2. Characteristic of the 9 Trials Included in the Meta-Analysis

Author(s)	Sample size (experimental/ control)	Patient enrollment time	Experimental	Control	Duration	Outcome measures
Chen et al., 2020	35/35	2020.2.28-2020.3.31	LHQW capsule (1.4 g Bid)	Arbidol	15 days	CT
Cheng et al., 2020	51/51	2020.1.1-2020.1.31	LHQW granule (6 g Tid) + C	Chemical drugs	7 days	CT, fever, cough, fatigue, expectoration, shortness of breath, dyspnea, chest distress, inappetence, nausea, muscular soreness, exacerbation rate
Fang et al., 2020	42/41	2020.1.28-2020.3.31	LHQW granule (6 g Tid) + C	Chemical drugs	5-7 days	Fever, fatigue, expectoration, shortness of breath, rhinobyon, rhinorrhea, muscular soreness
Hu et al., 2020	142/142	2020.2.2-2020.2.15	LHQW capsule (1.4 g Tid) + C	Chemical drugs	14 days	CT
Lv et al., 2020	63/38	2020.1.1-2020.2.28	LHQW granule (6 g Tid) + C	Chemical drugs	10 days	Expectoration, shortness of breath, dyspnea, chest distress, rhinobyon, rhinorrhea, sore throat, inappetence, nausea, emesis, diarrhea, muscular soreness, headache, exacerbation rate
Xu et al., 2020	26/26	2020.1.29-2020.2.28	LHQW capsule (1.4 g Tid) + C	Chemical drugs	7 days	CT
Yao et al., 2020	21/21	2020.1.11-2020.1.30	LHQW granule (6 g Tid) + C	Chemical drugs	NR	Fever, cough, fatigue, expectoration, shortness of breath, dyspnea, chest distress, rhinobyon, rhinorrhea, sore throat, inappetence, nausea, emesis, diarrhea, muscular soreness, headache


---

Yu and Li et al., 147/148 2020	2020.2.17-2020.3.6	LHQW granule (6 g Tid) + C	Chemical drugs	7 days	CT, exacerbation rate
Yu and Ren et al., 85/38 2020	2020.2.17-2020.3.6	LHQW capsule (1.4 g Tid)	Arbidol	Indeterminacy	Exacerbation rate


---

Notes: C: control group; NR: not reported.





**Appendix 4. Inverted Funnel Plot of LHQW in Treatment of COVID-19 for Disappearance Rate of Primary Symptoms**



**Appendix 5. Forest Plot of the Trials Showing Adverse Reaction in LCWC vs. CD**